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Abstract
Background: Recent evidence suggests that lobular carcinoma in situ (LCIS) can be a clonal precursor of invasive
breast cancers of both the ductal and lobular phenotypes. We sought to confirm these findings with an extensive
study of fresh frozen breast specimens from women undergoing mastectomy.
Methods: Patients with a history of LCIS presenting for therapeutic mastectomy were identified prospectively. Frozen
tissue blocks were collected, screened for lesions of interest, and subjected to microdissection and DNA extraction.
Copy number profiling, whole-exome sequencing, or both were performed. Clonal relatedness was assessed using
specialized statistical techniques developed for this purpose.
Results: After exclusions for genotyping failure, a total of 84 lesions from 30 patients were evaluated successfully. Strong
evidence of clonal relatedness was observed between an LCIS lesion and the invasive cancer for the preponderance of
cases with lobular carcinoma. Anatomically distinct in situ lesions of both ductal and lobular histology were also shown
to be frequently clonally related.
Conclusions: These data derived from women with LCIS with or without invasive cancer confirm that LCIS is commonly
the clonal precursor of invasive lobular carcinoma and that distinct foci of LCIS frequently share a clonal origin, as do foci
of LCIS and ductal carcinoma in situ.
Keywords: Lobular carcinoma in situ, Clonal relatedness, Whole-exome sequencing, Copy number array, Breast cancer,
Premalignant lesions, Molecular pathology in clinical prevention
Background
Since the first description of lobular carcinoma in situ
(LCIS) by Foote and Stewart in 1941, the biological sig-
nificance of LCIS has remained controversial [1]. Initially
regarded as a direct precursor to invasive lobular carcinoma
(ILC), LCIS was treated by mastectomy. Subsequent reports
from the 1970s and 1980s demonstrated that the rate of
breast cancer development following a diagnosis of LCIS
was lower than expected for a direct precursor lesion
(approximately 1 % per year) and was conferred equally
to both breasts [2, 3]. This generated controversy regarding
the significance of these lesions and led to disparate
recommendations for optimal management, ranging from
observation only to bilateral mastectomy [4–6].
In current practice, a diagnosis of LCIS is typically per-
ceived as a risk factor rather than a precursor of subse-
quent carcinoma, and, as such, radical treatment has
fallen out of favor [7]. Yet, molecular data demonstrating
that LCIS is a clonal neoplastic proliferation that com-
monly harbors the same genetic aberrations as those
found in adjacent invasive cancers have reinstated the
notion that LCIS is both a nonobligate precursor and a
risk factor for invasive breast cancer [8–14]. Evidence
suggesting that LCIS is a precursor lesion includes com-
parative genomic hybridization studies demonstrating
losses on chromosomes 16q and 17p in both LCIS and
ILC [11–13]; truncating mutations in the E-cadherin gene
and loss of heterozygosity of the wild-type E-cadherin
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allele in LCIS and adjacent ILCs [8–10]; and recent studies,
including one by our group, demonstrating a clonal rela-
tionship in a small number of coexisting LCIS and ILC on
the basis of similarities in genome-wide copy number pro-
files [14].
In the present study, we sought to provide more de-
finitive evidence of the frequency of clonality between
LCIS and synchronous malignancies. Extensive sampling
of mastectomy specimens allowed us to explore the rela-
tionship between distinct foci of LCIS in cases with multi-
focal lesions, a unique clinical feature of LCIS reported in
more than 50 % of cases [15–17]. Copy number profiling
was attempted in all specimens with sufficient DNA. Fur-
ther, the advent of next-generation sequencing made it
possible to investigate the clonal relationship of concur-




Patients with a documented history of LCIS presenting
for therapeutic mastectomy between 2005 and 2014 who
provided informed consent were enrolled preoperatively
in Memorial Sloan Kettering Cancer Center institutional
review board-approved protocols (IRB 01-135, 99-030).
The cases reported in our earlier study [14] were ascer-
tained from 2005 to 2008. The cases reported here were
ascertained in the later period. There is no overlap in the
cases presented. Following standard clinical sampling, ran-
dom sampling of mastectomy specimens from all breast
quadrants was performed, generating up to ten fresh fro-
zen blocks per quadrant. Blocks were stored at −80 °C,
and standard hematoxylin and eosin-stained sections were
reviewed by the study pathologist (DG) to identify lesions
of interest (LCIS, with or without ductal carcinoma in situ
[DCIS], invasive ductal carcinoma [IDC], or ILC) accord-
ing to 2012 World Health Organization histologic criteria
[18]. Samples were anonymized before tissue processing.
Matched germline DNA was available from blood or nor-
mal tissue for all cases. Sample pairs were selected on the
basis of availability of an LCIS lesion and at least one
additional LCIS, ILC, DCIS, or IDC lesion. Our report is
restricted to pairs of lesions located in the same breast.
Microdissection and DNA extraction
Selected frozen samples were processed as previously
described [14]. Briefly, 10-μm-thick sections from repre-
sentative frozen samples were stained with hematoxylin
and the in situ and/or invasive lesions were microdis-
sected separately with a needle under a stereomicroscope
to ensure tumor cell enrichment [19]. The number of mi-
crodissected sections per case varied by lesion size and
cellularity, with an average of 35 sections per lesion (range
6–89). DNA was extracted from tissue samples using the
QIAamp DNA Micro Kit (QIAGEN, Valencia, CA, USA)
and from available blood samples using the QIAamp
DNA Blood Maxi Kit (QIAGEN). All samples were sub-
jected to quantity and quality control and then submitted
for array comparative genomic hybridization profiling
and/or whole-exome sequencing. In cases with sufficient
DNA, we performed both assays. In cases with insufficient
DNA for copy number profiling, only whole-exome se-
quencing was performed.
Copy number profiling
Digested DNA was labeled by random priming using
BioPrime reagents (Life Technologies, Carlsbad, CA, USA),
cyanine 5 (Cy5)-2′-deoxyuridine 5′-triphosphate (dUTP)
for tumor DNA, and Cy3-dUTP for normal DNA, and
then hybridized to Agilent Human 4 × 180 KM compara-
tive genomic hybridization arrays (Agilent Technologies,
Santa Clara, CA, USA) using matched normal genomic
DNA as a reference. Hybridized slides were scanned and
images quantified using Feature Extraction 8.5 software
(Agilent Technologies). Fluorescence ratios of the scanned
images were calculated, and the raw array profiles were
normalized versus total intensity and guanine-cytosine
content of the region hybridized to the probe, using a
LOESS-based method. Log ratios were segmented using
the Bioconductor [20] DNAcopy package [21]. The Bio-
conductor NoWaves package [22] was used to remove
wavy patterns in the arrays. Log ratios of every set of 12
adjacent probes were averaged to reduce the noise level.
Segments were called gains or losses if their average
exceeded 1 median absolute deviation of residuals above
or below the median genome-wide log ratio.
Whole-exome sequencing
When available, DNA from microdissected lesions and
matched normal DNA were subjected to whole-exome
capture with SureSelect Human All Exon v4 (Agilent
Technologies) using a validated protocol [23, 24]. An
average of 187 million 75-bp paired-end reads were gener-
ated on an Illumina HiSeq 2000 instrument (Illumina, San
Diego, CA, USA) for each sample, equivalent to a median
depth of 192 (range 94–369). Reads were aligned to the
reference human genome GRCh37 using the Burrows-
Wheeler Aligner (BWA v0.6.2) [25]. Local realignment
and quality score recalibration were performed using the
Genome Analysis Toolkit (GATK v3.1.1) [26]. Deduplica-
tion was performed using Picard (v1.92) [27]. Somatic
single nucleotide variants were identified using MuTect
(v.1.1.4) [28], and small somatic indels were defined using
VarScan2 (v2.3.6) [29] and Strelka (v3.1.1) [26]. Variants
found with >5 % global minor allele frequency in dbSNP
(build 137) were disregarded.
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Statistical analysis
Correlations in the pattern of allelic gains and losses
between lesions were evaluated using a method previously
developed by our team [30, 31]. Regions of allelic gain and
loss were estimated using a one-step version of the circu-
lar binary segmentation algorithm in which at most one
region of gain or loss was identified on each chromosome
arm [21]. The method involves examining individual con-
cordant gains or losses carefully to assess the evidence
that each concordant change could have originated from a
clonal (i.e., identical) somatic event. The closeness of iden-
tified paired copy number changes provides the primary
evidence for or against a clonal origin of the lesion pairs.
The results are aggregated, and a measure characterizing
the strength of evidence favoring clonality is calculated.
This measure is then benchmarked against the distribu-
tion of the measure in pairs of lesions from different pa-
tients to obtain a p value. Comparisons are reported for
pairs of lesions where both members of the pair were con-
sidered to have sufficient array quality. Arrays with no
clear evidence of any allelic gains and losses or a high
noise level relative to few called changes are excluded
from the Results section but included in Additional file 1.
We used two metrics: (1) percent gained or lost and (2)
75th percentile of |height| of gains or losses (at least ten
markers long) divided by the median absolute deviation of
the residuals. The quality was considered to be sufficiently
good if either the percent gained or lost was >10 % or
if the |height| percentile was >1.75 median absolute
deviation.
Statistical comparison of exome sequencing data in-
volved the use of a likelihood ratio test specially adapted
for clonality testing of this nature [32]. This test evaluates
the possibility that observed mutation matches could occur
by chance in independent tumors based on the marginal
probabilities of individual point mutations, estimated using
mutation frequencies observed in The Cancer Genome
Atlas (TCGA) [33]. This results in a p value testing the hy-
pothesis that the tumors are independent (i.e., a test for
clonal relatedness), with smaller values indicating stronger
evidence for clonality. Absence of matches suggests that
the tumors are independent.
We also used the exome sequencing results to impute
copy number profiles as a validation of the comparisons
obtained from the comparative genomic hybridization
arrays. We accomplished this by first selecting a set of
loci in the target regions of exome sequencing such that
consecutive loci were separated by 250 bases and the
coverage depth was at least 25 for all of the normal sam-
ples. The copy number log ratio data represent the loga-
rithm of the tumor to normal coverage depth at these loci.
We used LOESS normalization to correct for G+C arti-
facts by regressing the log ratio on the G+C percentage of
a 1-kilobase window centered at the locus. This gave us
the log ratio for approximately 227,000 loci spanning the
genome. Adjacent probes were averaged as before to re-
duce this to 14,603 markers, which we then analyzed using
the same statistical methods as described above for the
data obtained using comparative genomic hybridization.
These copy number plots are displayed in Additional file 2.
We elected to “call” cases as clonal using a “believe
the positive” rule, but with a strict significance level; that
is, a case was designated as clonal if either the mutation
profiling or the copy number comparison rejected the hy-
pothesis that the tumors were independent with p < 0.01.
If the smaller p value was in the 0.01–0.05 range, we called
the case “equivocal.”
Results
Using copy number arrays, we profiled a total of 125 tu-
mors from 50 cases. Whole-exome sequencing was also
performed for tumors for which sufficient DNA was
available, including one additional case with five tumors
not subjected to copy number profiling. The results of all
comparisons meeting quality control criteria described
above in the Methods section using either copy number
profiling or exome sequencing or both are presented in
Table 1. Details of all individual mutations identified are
provided in Additional file 3.
Clonal relatedness of LCIS and invasive breast cancers
The clonal relatedness of LCIS and ILC is strongly rep-
resented by both copy number and mutational analysis
(Table 1). A total of 16 pairings from 14 of the 19 cases
are definitively clonal on the basis of highly significant
tests comparing either the copy number profiles or the
mutational profiles, or both. A striking example is case
33. The copy number plots, reproduced in Fig. 1, show
strongly similar patterns of gains and losses in the LCIS
and ILC samples, and we identified 66 matching muta-
tions in whole-exome sequencing (Table 1). Similar plots
of all copy number comparisons, including those that
did not meet quality control criteria, are provided in
Additional file 1. Four pairs from three distinct cases
had no matching mutations, suggesting independence,
and three additional cases were judged to be independ-
ent on the basis of the copy number comparisons. The
copy number plots for one of these cases (case 31) are
shown in Fig. 2. There are matching whole arm gains in
chromosome 1q and matching whole arm losses in
chromosome 16q, but these allelic changes are emblem-
atic of LCIS lesions generally, and the statistical method
discounts the significance of these matches accordingly.
The other gains and losses in the two lesions are dis-
cordant. In the remaining two comparisons, we judged
the evidence not to be definitive (i.e., equivocal).
The results for pairings involving LCIS and IDC samples
are shown in Table 1. In total, nine comparisons from five
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Clonality test p values Diagnosis Shared
mutationsb
Tumor 1 Tumor 2 Mutationsa Copy number arraysc CDH1 PIK3CAd
LCIS-ILC
13 50 LCIS1-ILC No 1.6 16/3300 16/56 <0.001 0.002 Clonal – –
24 57 LCIS1-ILC Yes 2.1 25/36 25/34 <0.001 <0.001 Clonal √ √
LCIS2-ILC No 2/29 2/34 <0.001 Clonal – –
28 60 LCIS-ILC Yes 0.12 0.93 Independent
31 69 LCIS-ILC Yes 1.5 0.31 Independent
33 65 LCIS-ILC Yes 2.1 66/81 66/1015 <0.001 <0.001 Clonal – –
35 72 LCIS-ILC Yes 4.7 <0.001 Clonal
38 73 LCIS2-ILC Yes Missing 23/527 23/615 <0.001 0.54 Clonal – –
42 52 LCIS-ILC Yes 2.3 56/119 56/109 <0.001 Clonal √ √
LCIS2-ILC Yes 0.01 Equivocal
43 41 LCIS-ILC Yes 1.9 0.001 Clonal
45 55 LCIS-ILC Yes 12.2 <0.001 Clonal
46 51 LCIS-ILC Yes 4.5 0/46 0/15 1.0 Independent
LCIS3-ILC No 0/37 0/15 1.0 Independent
47 51 LCIS1-ILC No 1.5 7/29 7/25 <0.001 <0.001 Clonal √ –
LCIS2-ILC No 7/22 7/25 <0.001 0.42 Clonal √ –
48 37 LCIS1-ILC Yes 6.0 20/33 20/40 <0.001 <0.001 Clonal √ –
LCIS2-ILC No 1/22 1/40 0.03 0.10 Equivocal – –
52 50 LCIS-ILC Yes 1.9 0.005 Clonal
LCIS2-ILC Yes 0.05 Independent
55 72 LCIS-ILC Yes 1.3 6/31 6/36 <0.001 0.002 Clonal – √
68 48 LCIS1-ILC No 1.4 0/44 0/33 1.0 0.58 Independent – –
69 56 LCIS-ILC Yes 3.0 18/56 18/31 <0.001 0.001 Clonal √ √
73 44 LCIS1-ILC Yes 0.5 0/26 0/42 1.0 Independent
75 58 LCIS1-ILC Yes 3.5 15/46 15/39 <0.001 Clonal √ √
LCIS-IDC
26 54 LCIS-IDC No 1.8 0/29 0/32 1.0 Independent
47 51 LCIS1-IDC No 1.0 1/29 1/30 0.02 0.35 Equivocal – –
LCIS2-IDC No 1/22 1/30 0.03 0.48 Equivocal – –
53 41 LCIS1-IDC Yes 3.7 2/20 2/23 <0.001 0.40 Clonal – –
LCIS2-IDC Yes 1/15 1/23 0.02 0.62 Equivocal – –
74 61 LCIS1-IDC Yes 0.75 0/32 0/34 1.0 0.50 Independent – –
LCIS2-IDC No 0/37 0/34 1.0 0.73 Independent – –
LCIS3-IDC No 3/42 3/34 <0.001 Clonal – –
75 58 LCIS2-IDC Yes 1.8 0/22 0/29 1.0 Independent – –
LCIS-LCIS
4 44 LCIS1-LCIS2 No N/A 11/46 11/30 <0.001 Clonal – –
5 67 LCIS1-LCIS2 No N/A 0.85 Independent
8 47 LCIS1-LCIS2 No N/A 9/34 9/25 <0.001 Clonal – –
17 48 LCIS1-LCIS2 No N/A 13/26 13/27 <0.001 Clonal √ –
19 43 LCIS1-LCIS2 No N/A 12/24 12/185 <0.001 Clonal – –
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distinct cases were available for LCIS and one or more
IDCs. Six pairings with copy number data met our quality
control criteria, but these comparisons failed to provide
evidence of clonality. However, shared mutational events
were evident in five of nine pairwise comparisons, and for
two of the five distinct cases, there was strongly significant
evidence of clonal relatedness for at least one LCIS-IDC
pairing. Yet, the number of matches in the various pair-
ings ranged from one to three, substantially fewer than the
number of matches typically observed in the LCIS-ILC
comparisons.
Clonal relatedness of distinct in situ lesions
Extensive sampling of mastectomy specimens allowed us
to generate 18 pairs of anatomically distinct LCIS lesions
from 15 patients (Table 1). The copy number plots were
frequently of poor quality in one or the other of the
specimens in the pair, but the whole-exome sequencing
data provide strong evidence of clonal relatedness in the
preponderance of cases examined (12 of 18 comparisons
in 11 of 15 distinct cases), including several cases where
the lesions were harvested from anatomically distinct
quadrants of the breast. Similarly, in the 13 comparisons
from 8 distinct cases with both LCIS and DCIS lesions,
we identified strong evidence of clonal relatedness in 9
comparisons from 5 cases (Table 1), again with evidence
of clonal relatedness in lesions harvested from different
quadrants of the breast.
Further observations from exome profiling
Exome sequencing permits the derivation of copy num-
ber arrays, serving as a validation of the results from the
Table 1 Results of all comparisons meeting quality control criteria (Continued)
24 57 LCIS1-LCIS2 No N/A 0/36 0/28 1.0 Independent – –
38 73 LCIS1-LCIS2 Yes N/A 23/174 23/527 <0.001 Clonal – –
46 51 LCIS-LCIS3 No N/A 5/46 5/37 <0.001 Clonal – –
47 51 LCIS1-LCIS2 Yes N/A 8/29 8/22 <0.001 0.59 Clonal √ –
48 37 LCIS1-LCIS2 No N/A 0/33 0/22 1.0 0.59 Independent – –
52 50 LCIS-LCIS2 Yes N/A 13/28 13/34 <0.001 0.02 Clonal √ √
53 41 LCIS1-LCIS2 Yes N/A 6/21 6/17 <0.001 0.005 Clonal √ –
59 47 LCIS-LCIS2 No N/A 12/31 12/26 <0.001 0.10 Clonal √ –
73 44 LCIS3-LCIS4 No N/A 0/14 0/11 1.0 Independent
74 61 LCIS1-LCIS2 No N/A 0/32 0/37 1.0 0.02 Independent – –
LCIS1-LCIS3 No N/A 1/34 1/43 0.03 Equivocal – –
LCIS2-LCIS3 No N/A 24/37 24/42 <0.001 Clonal √ –
LCIS4-LCIS5 No N/A 14/41 14/47 <0.001 Clonal – –
LCIS-DCIS
04 44 LCIS1-DCIS1 Yes N/A 15/46 15/703 <0.001 <0.001 Clonal – –
LCIS2-DCIS1 No N/A 10/30 10/703 <0.001 Clonal – –
LCIS1-DCIS2 No N/A 13/46 13/24 <0.001 <0.001 Clonal – –
LCIS2-DCIS2 Yes N/A 8/30 8/24 <0.001 Clonal – –
06 57 LCIS-DCIS Yes N/A 6/50 6/75 <0.001 0.81 Clonal – –
16 62 LCIS-DCIS No N/A 0/92 0/57 1.0 Independent – –
26 54 LCIS-DCIS No N/A 0/29 0/34 1.0 0.14 Independent – –
47 51 LCIS1-DCIS Yes N/A 3/29 3/23 <0.001 0.71 Clonal – –
LCIS2-DCIS Yes N/A 0/22 0/23 1.0 0.03 Independent – –
59 47 LCIS-DCIS Yes N/A 6/31 6/31 <0.001 0.74 Clonal – –
LCIS2-DCIS No N/A 2/26 2/31 0.003 0.67 Clonal – √
68 48 LCIS1-DCIS Yes N/A 8/44 8/33 <0.001 0.03 Clonal – –
75 58 LCIS2-DCIS Yes N/A 0/22 0/38 1.0 Independent – –
aA blank entry indicates that whole-exome sequencing was not performed
bIn cases with shared mutations “√” represents the presence of a shared mutation in the designated gene, while a dash represents its absence
cCopy number comparisons using Agilent comparative genomic hybridization. A blank entry indicates that one or more of the copy number profiles did not meet
our quality control criteria (except for case 75, for which copy number profiling was not performed)
dNote that only seven cases are listed with a PIK3CA match, versus eight in Table 2. The additional match occurred between the two ductal lesions in case 47
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Agilent comparative genomic hybridization approach
for those cases with sequencing available. The copy
number segmentation plots are provided in Additional
file 2, and these can be compared with the corresponding
copy number plots obtained from comparative genomic
hybridization, which are available in Additional file 1. The
table in Additional file 4 compares the p values obtained
from these two methods side by side. Although there is
clearly considerable variation in the actual p values ob-
served, the results are broadly consistent.
The results from the cases with exome sequencing also
provide some novel insights into the typical mutational
profiles of the distinct lesions and the roles that individual
genes may play. We tabulated the frequencies at which
mutations were observed in individual genes among the
20 cases with tumors sequenced, and the results are sum-
marized in Table 2. A mutation was designated as “clonal”
if it was observed in two or more tumors from the patient.
A mutation was designated as “private” if it was observed
in at most one tumor from the patient. The relative fre-
quencies of clonal and private mutations are displayed in
Table 2, where the genes are ranked on the basis of overall
mutation frequency. This table was constructed after ex-
cluding the 5 tumors that were hypermutated with >200
mutations (see Additional file 3) as well as an outlier gene
(FSIP2) that exhibited 13 nonfunctional mutations in 2
cases. The table shows clearly that the most common
driver mutations, CDH1 (E-cadherin) and PIK3CA, have
high percentages of clonal mutations, but that the relative
frequency rapidly drops to the overall average of <20 %.
CBFB also exhibits a high relative frequency of clonal mu-
tations. Clearly the preponderance of “clonal” mutations
occur in a very broad spectrum of genes largely unrelated
to the genes’ propensity to harbor somatic mutations. It is
also noteworthy that all but one of the clonal mutations in
CDH1 and PIK3CA occurred in pairs involving lobular le-
sions (see Table 1 for the specific cases in which clonal
mutations occurred in these genes). Indeed, for all 16 pa-
tients with mutations in CDH1, the mutations occurred in
lobular lesions.
All of the 37 mutations observed in either of the two
most frequently mutated genes, CDH1 and PIK3CA,
were functional (nonsynonymous, truncating, or non-
sense as opposed to synonymous). This compares with a
baseline relative frequency of functional mutations of
69 % across all genes, a frequency essentially unrelated
to the overall mutation frequencies of the genes after ex-
cluding these two genes (Table 2). Interestingly, we see
no evidence that clonal mutations are more likely than
private mutations to be functional. The overall mutational
burdens of the distinct tumor types were also similar. The
median numbers of mutations per lesion were 33 for
Fig. 1 Copy number comparisons for case 33. Plots show similar copy number aberrations in both invasive lobular carcinoma (ILC) and lobular
carcinoma in situ (LCIS) lesions for case 33. The x-axis is ordered by chromosome, and the y-axis is the log ratio, representing the allele count,
with areas of gains and loss represented by blue and red lines, respectively. Similar gains and losses were observed in both ILC and LCIS lesions
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LCIS, 38 for ILC, 29 for IDC, and 33 for DCIS, numbers
that are not significantly different.
Discussion
Lobular carcinoma in situ is a noninvasive neoplastic le-
sion of the breast characterized by distention of the lob-
ules and terminal ductal lobular units by a proliferation
of atypical but monomorphic dyshesive cells [1, 34]. It is
most frequently diagnosed in women aged 40–55 years
[2] as an incidental finding in benign breast biopsies, re-
ported in 0.5–4.0 % of cases [15, 35, 36], but the true
prevalence of LCIS in the general population is likely to
be higher. Although LCIS is typically perceived as a
marker of increased breast cancer risk [37], emerging
evidence of genotypic similarities between coexisting LCIS
and invasive lobular breast cancer suggests that a subset
of LCIS may carry a higher risk for progression to invasive
disease, exhibiting true precursor potential [8–14]. Using
a combination of copy number profiling and whole-exome
sequencing in this study, we have demonstrated strong
clonal relationships between multiple foci of LCIS and
DCIS as well as LCIS and ILC, confirming that LCIS is
commonly the clonal precursor of ILC, with distinct foci
of LCIS frequently sharing a clonal origin. Furthermore,
the mutational data exhibit large numbers of mutations in
both the LCIS and DCIS samples, with absolute numbers
similar to the mutational burdens of invasive cancers. The
dominant influence of mutations in CDH1 and PIK3CA
reflects the recent results from TCGA showing that these
two genes harbor by far the most frequently recurring mu-
tations in lobular breast cancer [38].
The clinical characteristics of LCIS that have long sup-
ported its role as a risk factor for the subsequent devel-
opment of breast cancer include a cumulative long-term
risk that is generally conferred equally to both breasts,
averaging 1–2 % per year, and the observation that not
all breast cancers developing after a diagnosis of LCIS
have lobular histology [39, 40]. However, in some studies,
researchers have reported a higher rate of breast cancer in
the ipsilateral breast [41, 42], and in these studies the ma-
jority of the cancers reported have lobular histology,
supporting a precursor role for LCIS. This clinical obser-
vation, in parallel with Surveillance, Epidemiology, and
End Results data demonstrating an increasing incidence of
both LCIS and ILC from the late 1980s to the mid-1990s
among women 50 years of age and older [43], has gener-
ated renewed interest in the debate over the clinical sig-
nificance of LCIS.
Previous investigations provided suggestive evidence
about the clonal relationships between LCIS and related
breast tumors, especially ILC, using a variety of genetic
techniques [8–14]. In our present study, by using whole-
exome sequencing in selected cases, we provide excep-
tionally convincing evidence of clonal relatedness in
Fig. 2 Copy number comparisons for case 31. Plots show distinct copy number changes for case 31, except for the ubiquitous 1q gains and 16q
losses seen in most lobular carcinoma in situ (LCIS) lesions
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multiple cases. Since whole-exome sequencing allowed
us to detect precise mutational matches, and since the
specific locations of the vast majority of somatic muta-
tions are exceptionally rare, the occurrence of more than
one match is extremely unlikely to occur by chance, un-
less the matches occur at one of the very few mutational
hot spots. We observed many cases of tumor pairs with
multiple matches, providing overwhelming evidence of
clonality in these cases. Our results indicate very strong
clonal relationships not only between LCIS and invasive
lobular cancers but also among anatomically distinct in
situ lesions, including LCIS and DCIS lesions, as has
been suggested in previous studies [14, 44]. We also saw
evidence of clonality between LCIS and IDC, though the
numbers of matching mutations were small and the evi-
dence for clonality was not supported by the copy num-
ber comparisons.
We do acknowledge that mutation calling artifacts can
occur due to germline mutations that are not recognized
as such or due to misalignment in a region that is diffi-
cult to sequence. Therefore, caution must be taken in
interpreting results in pairs with very few shared muta-
tions. We further caution that our LCIS cases should
not be considered to be representative of typical LCIS en-
countered in women without invasive cancers. In this study,
we ascertained the LCIS specimens from mastectomies
Table 2 Mutation frequenciesa
Gene Mutations per geneb (20 cases) Percent functional mutationsc
Mutations Casesd Clonal Private Percent clonal Clonal Private
CDH1 24 16 11 13 54 % 11/11 100 % 13/13 100 %
PIK3CA 13 11 9 4 9/9e 4/4
SPRR3 10 9 1 9 30 % 1/1 55 % 1/9 70 %
CBFB 10 8 7 3 6/6 3/3
GATA3 9 6 2 7 2/2 6/7
NBPF1 8 8 2 6 2/2 4/6
MUC12 7 5 1 6 0/1 4/6
KMT2C 6 6 1 5 1/1 4/5
MUC4 6 5 2 4 0/2 3/4
TCEAL3 6 4 5 1 0/5 0/1
MAP3K1 6 4 3 3 3/3 3/3
BCLAF1 5 5 0 5 0/5 5/5
HMCN1 5 5 0 5 0/0 3/5
TMPRSS13 5 4 1 4 1/1 4/4
REXO1L1 4 4 0 4 13 % 0/0 75 % 0/4 79 %
TDG 4 4 0 4 0/0 3/4
DDX11 4 4 1 3 1/1 2/3
ABCC5 4 4 0 4 0/0 3/4
MACF1 4 4 0 4 0/0 4/4
AGGF1 4 4 1 3 1/1 3/3
OR13C2 4 2 0 4 0/0 4/4
NASP 4 2 0 4 0/0 4/4
SERPINA3 4 2 0 4 0/0 4/4
28 genes 3 3 14 70 10/14 50/70
159 genes 2 2 69 249 16 % 50/69 72 % 164/249 66 %
1477 genes 1 1 224 1253 158/224 71 % 854/1253 68 %
aThis table includes only the 20 cases with exome sequencing results available. Data from five tumors that were hypermutated are excluded: case 4 (DCIS1), case
13 (LCIS), case 33 (ILC), case 38 (LCIS), and case 38 (ILC)
bIf a mutation was observed in two or more tumors from the case, it was designated a “clonal” mutation. If it was detected in a single tumor from the case, it was
designated “private.” Note that the sum of clonal and private mutations can exceed the number of cases, since more than one distinct mutational locus can occur
in the same patient or even in the same tumor
cThe category “functional” excludes synonymous mutations
dThis represents the number of cases in which one or more tumors possess mutations in the designated gene
eWe note that two of the nine clonal PIK3CA mutations occurred in pairs of ductal tumors
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conducted to remove a diagnosed invasive cancer. Conse-
quently, it is probable that our study overrepresents the
LCIS lesions that progress. Furthermore, we evaluated the
mutational profiles at the time of breast cancer diagnosis. It
is plausible that the mutational burdens would be lower in
LCIS tumors found earlier in the disease process.
For many cases in our study, we used both copy number
profiling and mutational testing to evaluate the clonal re-
latedness of the tumors. Typically, though not always, the
results from these two methods are congruent. However,
in several cases, mutational profiling demonstrated strong
evidence of clonality, while copy number profiling did not.
We used a “believe the positive” rule in these cases, since
the presence of multiple mutational matches is extraor-
dinarily unlikely to occur by chance and thus provides
strong evidence of clonal relatedness. There were no ex-
amples where the copy number profiles were strongly
clonal while the mutational data were not. This may be
because the copy number approach is less sensitive in de-
tecting somatic events due to noise in the data, even
though we excluded many cases for excessive noise. It is
also possible that the early events in breast tumorigenesis
are more typically mutational events and that the copy
number gains and losses tend to occur later. Indeed, it is
possible that cases we called “independent” based solely
on nonsignificant copy number comparisons without
exome data could be false-negatives for this reason.
Our broader exploratory analyses of the mutational
spectra observed in the subset of cases with exome se-
quencing produced some interesting findings. The most
frequently mutated gene is the E-cadherin gene (CDH1),
known to be silenced in most LCIS tumors, through either
allelic losses of chromosome 16q or the presence of a mu-
tation [45]. Our results showed no ductal lesions harbor-
ing a mutation in CDH1, confirming the diagnostic
contrast of this gene in ductal versus lobular in situ lesions
[46]. In the most commonly mutated genes, the frequen-
cies of “clonal” mutations relative to “private” mutations
were notably higher than the collective relative frequency
for the very large number of genes that occurred infre-
quently. Since the clonal mutations must have occurred
early in tumor development, this confirms the importance
of these common mutations as driver mutations. The two
genes with the highest frequencies of occurrence, CDH1
and PIK3CA, were in this category. However, after exclud-
ing these genes, there was very little remaining correlation
between the overall prevalence of gene mutations and the
relative frequency of clonal mutations, suggesting that
many mutations that occurred in the originating clonal
cell may actually be passenger mutations. This notion is
further buttressed by the fact that the relative frequencies
of functional to nonfunctional mutations did not appear
to be different for clonal versus private mutations. There
appeared to be little overall difference in the mutational
burden of in situ versus invasive cancers. All four groups
of tumors had a similar mutational burden overall.
Taken together, our observational and molecular data
support the contention that LCIS is not only a risk indica-
tor but also a nonobligate precursor of invasive breast
cancer. In particular, the presence of concordant gene copy
number changes and identical mutations in matched LCIS
and ILC from the same patients, as demonstrated here,
supports the premise that the majority of LCIS lesions
found in association with ILC are in fact true precursor
lesions. With increasing numbers of women presenting
with LCIS, a better understanding of the malignant poten-
tial and factors that may alter the risk of breast cancer
development are paramount to appropriately counseling
women with this lesion.
Conclusions
LCIS has traditionally been considered to be a marker of
invasive breast cancer risk rather than a precursor lesion.
Our study provides definitive evidence that LCIS is fre-
quently a precursor lesion. Furthermore, the mutational
spectra of the LCIS lesions in our study were broadly indis-
tinguishable from those of the invasive carcinomas. These
results suggest that LCIS lesions have the hallmarks of
invasive cancers. Our present findings provide important
insights for clinicians who counsel women with LCIS re-
garding breast cancer prevention options.
Additional files
Additional file 1: Separate plots are provided for copy number
comparisons of all pairs of lesions ascertained in the study, including
those comparisons not presented in the main text because one or other of
the tumors in the pair was considered to have insufficient quality. We used
two quality metrics: percent gained or lost; 75th percentile of |height| of
gains or losses (at least ten markers long) divided by the median absolute
deviation of the residuals. The quality was considered to be sufficiently good
if either the percent gained or lost was >10 % or if the |height| percentile
was >1.75 median absolute deviation. The figures display the log ratios for
each marker ordered across the genome, side by side for each tumor in the
pair. The blue lines indicate regions of allelic gain, and the red lines indicate
regions of allelic loss, as determined by the segmentation algorithm used
[21]. (PDF 19100 kb)
Additional file 2: Separate plots are provided for copy number
comparisons imputed from the exome sequencing platforms for all
cases where good-quality data were obtained from use of both this
method and the method based on comparative genomic hybridization.
These plots can be compared with the corresponding plots obtained
using comparative genomic hybridization in Additional file 1. For most
tumors, the copy number patterns derived from the two methods are very
similar. p Values are compared in the table in Additional file 4. (PDF 7994 kb)
Additional file 3: Details of all individual mutations detected by exome
sequencing. (XLSX 756 kb)
Additional file 4: This table compares the p values obtained from the
clonality tests based on copy number profiling derived using comparative
genomic hybridization and the exome arrays. Although there is clearly
considerable variation in the actual p values observed, there is consistency
in identifying strong clonality signals (p < 0.01), except for case 48
(LCIS2-ILC). (DOCX 28 kb)
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